- Home
- MCI vs SAGE Comparison
MCI vs SAGE Comparison
Compare MCI & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- SAGE
- Stock Information
- Founded
- MCI 1971
- SAGE 2010
- Country
- MCI United States
- SAGE United States
- Employees
- MCI N/A
- SAGE N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- MCI Finance
- SAGE Health Care
- Exchange
- MCI Nasdaq
- SAGE Nasdaq
- Market Cap
- MCI 400.8M
- SAGE 444.1M
- IPO Year
- MCI N/A
- SAGE 2014
- Fundamental
- Price
- MCI $23.25
- SAGE $7.31
- Analyst Decision
- MCI
- SAGE Hold
- Analyst Count
- MCI 0
- SAGE 20
- Target Price
- MCI N/A
- SAGE $10.67
- AVG Volume (30 Days)
- MCI 40.4K
- SAGE 1.8M
- Earning Date
- MCI 01-01-0001
- SAGE 02-11-2025
- Dividend Yield
- MCI 8.46%
- SAGE N/A
- EPS Growth
- MCI N/A
- SAGE N/A
- EPS
- MCI 1.82
- SAGE N/A
- Revenue
- MCI N/A
- SAGE $41,243,000.00
- Revenue This Year
- MCI N/A
- SAGE $123.13
- Revenue Next Year
- MCI N/A
- SAGE $69.65
- P/E Ratio
- MCI $9.88
- SAGE N/A
- Revenue Growth
- MCI N/A
- SAGE N/A
- 52 Week Low
- MCI $12.96
- SAGE $4.62
- 52 Week High
- MCI $19.24
- SAGE $23.22
- Technical
- Relative Strength Index (RSI)
- MCI 62.89
- SAGE 60.55
- Support Level
- MCI $21.00
- SAGE $7.00
- Resistance Level
- MCI $21.33
- SAGE $7.26
- Average True Range (ATR)
- MCI 0.79
- SAGE 0.19
- MACD
- MCI 0.29
- SAGE -0.06
- Stochastic Oscillator
- MCI 57.11
- SAGE 57.14
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. These investments are typically made to small or middle market companies. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.